ESMO26: Sac-TMT sets survival benchmark in recurrent endometrial cancer
Data for MSD and Kelun-Biotech's sac-TMT in endometrial cancer was presented at ESMO 2026.
Comment & Opinion
ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
ESMO26: Bayer’s Phase III Nubeqa win leaves survival and abiraterone questions open
ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer
ESMO26: Oral cell cycle inhibitors place Cyclin E1 as new target in PROC
Egypt reforms obsolete pharmaceutical pricing framework
Danish fast-track model inspires growth in national reimbursement rates
Global systems unprepared for rising threat of invasive fungal infections
